UNIT · peptides · standard · freshness 90d
BPC-157 — Current Research Position, Dosage Patterns, and Safety Profile
Where the BPC-157 evidence base stands as of 2026 — animal data, limited human reports, common dosage patterns in research literature, and the regulatory and safety picture.
PREVIEW · free to read
Educational summary of the published research literature. BPC-157 is not an approved human therapeutic in the US, EU, UK, or Australia. Nothing here is medical advice — consult a qualified clinician for individual decisions.
What it is
BPC-157 ("Body Protection Compound 157") is a 15-amino-acid synthetic peptide derived from a sequence in human gastric juice. The bulk of published research is preclinical (rodent), with a small number of early human case reports.
Evidence base — what exists
- Tendon and ligament healing. Multiple rodent studies (Sikiric et al., 2003 onward) report accelerated healing of transected Achilles tendons and medial collateral ligaments after injected or oral BPC-157.
- Gastrointestinal protection. Rodent models show reduced damage from NSAIDs, alcohol, and stress; mechanisms include nitric oxide pathway modulation.
- Vascular effects. Reported angiogenic activity in wound and ischemia models.
Evidence base — what's missing
- No completed phase II…
Pay with credits — log in or sign up at /account and use
Authorization: Bearer ck_… on
/api/units/bpc-157-dosage-safety-2026. Or, for browser convenience:
Of every $0.0050, the producer earns 90% · Caiche keeps 10% as marketplace fee.
Browser purchase is a stub — replace with a real Stripe-funded credit balance for production use.
Sources
Related units
Nearest neighbours by topic similarity in the same corpus.
What TB-500 is, what the published research on Thymosin Beta-4 actually supports, the gap between the parent molecule and the truncated TB-500 fragment, and the regulatory and safety picture in 2026.
How CJC-1295 and ipamorelin work, why they are commonly stacked, what the published research supports, and the regulatory and safety picture as of 2026.
Summary of recent (late 2025 – early 2026) trial readouts for incretin-based metabolic drugs — retatrutide, ecnoglutide, mazdutide, MariTide. Efficacy, safety, and how they compare to semaglutide / tirzepatide.
Both are GHRH analogs; one is a short-acting compounded option, the other is the only FDA-approved GHRH for a specific lipodystrophy indication. How they differ in pharmacology, approved use, and current availability.
How the GLP-1 class has evolved through 2026 — single-pathway agonists (semaglutide), dual GLP-1/GIP (tirzepatide), and triple GLP-1/GIP/glucagon (retatrutide). Efficacy, side effects, and where each currently fits.
GET /api/units/bpc-157-dosage-safety-2026
with Authorization: Bearer ck_… debits your balance and returns full content.